N@N

KNDL, WBD, UTHR, CMCSK, SVNT, SWKS Are Seasonally Ripe To Go Up In the Next Five Weeks

May 10, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of KENDLE INTERNATIONAL INC (NASDAQ:KNDL), WIMM-BILL-DANN FOODS-ADR (NYSE:WBD), UNITED THERAPEUTICS CORP (NASDAQ:UTHR), COMCAST CORP-SPECIAL CL A (NASDAQ:CMCSK), SAVIENT PHARMACEUTICALS INC (NASDAQ:SVNT), SKYWORKS SOLUTIONS INC (NASDAQ:SWKS) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Up:

     Symbol     Company                             Expected Return     Odds                    By The Following Date
     KNDL       KENDLE INTERNATIONAL INC            10.48%              69.23% (9 of 13)        Wednesday, June 22nd 2011
     WBD        WIMM-BILL-DANN FOODS-ADR            6.90%               77.78% (7 of 9)         Thursday, June 2nd 2011
     UTHR       UNITED THERAPEUTICS CORP            10.45%              72.73% (8 of 11)        Tuesday, June 14th 2011
     CMCSK      COMCAST CORP-SPECIAL CL A           6.23%               66.67% (16 of 24)       Thursday, June 16th 2011
     SVNT       SAVIENT PHARMACEUTICALS INC         8.76%               65.00% (13 of 20)       Thursday, June 2nd 2011
     SWKS       SKYWORKS SOLUTIONS INC              6.53%               65.85% (27 of 41)       Friday, June 3rd 2011

KENDLE INTERNATIONAL INC (NASDAQ:KNDL) - Kendle International Inc., a clinical research organization, provides Phase I-IV clinical development services on a contract basis to the biopharmaceutical industry worldwide. The company operates through two segments: Early Stage and Late Stage. The Early Stage segment focuses on the high-end scientific exploratory medicine area, from first-in-human studies to proof-of-concept stages. This segment also supports Phase I studies in established compounds, including bioequivalence and pharmacokinetics studies. The Late Stage segment conducts Phase II to IV clinical trials, as well as provides a range of services, including clinical monitoring, investigator recruitment, patient recruitment, data management, and study reports to assist customers with their drug development process. This segment also oversees various steps of a study, from award to close out of a study; designs and conducts Phase IIIB and IV studies; focuses on health economics and outcomes research, observational studies, scientific events, and medical education services; and provides services to the federal government and health care foundation oriented organizations. In addition, it offers regulatory and consulting services at every stage of drug and device development, as well as designs clinical programs and clinical trial protocols, reviews programs, and provides gap analysis to assist sponsors in achieving their clinical development strategies; offers consulting services for nonclinical development for small molecules, biologicals, vaccines, and devices; assists with the U.S. Food and Drug Administration application process; and assists customers with the collection, analysis, and reporting of drug safety data. Further, this segment offers statistical support for Phase I to IV clinical trials and submissions. Kendle International Inc. operates in North America, Europe, Asia/Pacific, Latin America, and Africa. The company was founded in 1981 and is based in Cincinnati, Ohio.

WIMM-BILL-DANN FOODS-ADR (NYSE:WBD) - Wimm-Bill-Dann Foods OJSC manufactures and sells dairy, beverage, and baby food products primarily in the Russian Federation. Its principal dairy products include sterilized and pasteurized milk, and butter and cream, as well as traditional sour-milk products, such as kefir, cottage cheese, soft cottage cheese, and sour cream; yogurts and dairy desserts, such as traditional and drinking yogurt, fruit-flavored milk, puddings, and flavored cottage cheese; and cheese products, including hard yellow and processed cheese. The companys beverage products primarily comprise juices and nectars produced from juice concentrates; enriched juice-based drinks; Mors, a traditional berry-juice-based drink made from natural berries; bottled natural mineral water; and drinking water. Its baby food products consist of liquid dairy products, and juices and water for infants under the age of three; meat, fish, poultry, fruit, vegetable, and dairy purees for children aged three and under; dry formula for feeding babies; products for pregnant women and nursing mothers; and other food products for children. The company sells its products through various sales channels, including independent distributors and wholesalers, supermarket chains, small and medium-sized grocery stores, open air markets, pavilions, and restaurants and cafes. Wimm-Bill-Dann Foods OJSC was founded in 1992 and is based in Moscow, the Russian Federation. As of February 3, 2011, Wimm-Bill-Dann Foods OJSC operates as a subsidiary of Pepsi-Cola (Bermuda) Limited.

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and Internationally. It offers Remodulin, Tyvaso, and Adcirca (tadalafil) tablets for the treatment of pulmonary arterial hypertension (PAH); and CardioPAL SAVI and decipher cardiac monitors, and CardioPAL SAVI wireless cardiac event monitors for cardiac arrhythmias and ischemic heart disease. The companys under development products include Oral Treprostinil, which is in Phase III clinical trials for the treatment of PAH and is in Phase II clinical trials for the treatment of peripheral vascular disease; Beraprost-MR, a Phase II clinical trials product for the treatment of PAH; 3F8 MAb, a Phase II clinical trials product for neuroblastoma; Aviptadil, a Phase II clinical trials product targeting pulmonary hypertension and other pulmonary diseases; 8H9 MAb, a Phase I clinical trials product for the treatment of metastatic brain cancer; IW001, a Phase I clinical trials product that targets idiopathic pulmonary fibrosis and primary graft dysfunction; and Glycobiology Antiviral Agents, which are in pre-clinical trials for Hepatitis C and other infectious diseases. United Therapeutics Corporation also provides telemedicine monitoring services to detect cardiac arrhythmias and ischemic heart disease. The company sells its products through sales and marketing staff, specialty pharmaceutical distributors, and pharmaceutical wholesalers. It has a licensing agreements and relationships with Eli Lilly and Company; Toray Industries, Inc.; NEBU-TEC; Mondobiotech; ImmuneWorks; GlaxoSmithKline PLC; Pfizer Inc.; and Supernus Pharmaceuticals, Inc. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

COMCAST CORP-SPECIAL CL A (NASDAQ:CMCSK) - Comcast Corporation, together with its subsidiaries, provides consumer entertainment, information, and communication products and services to the residential and commercial customers in the United States. The company operates in two segments, Cable and Programming. The Cable segment manages and operates cable systems, including video, high-speed Internet, and phone services, as well as regional sports and news networks. Its video services include analog, digital, on demand, and high-definition television and/or digital video recorders. This segments high-speed Internet service consists of an interactive portal, Comcast.net, which provides multiple email addresses and online storage, as well as various proprietary content, and value-added features and enhancements. Its phone services include voice over Internet protocol digital phone service that provides local and domestic long-distance calling with various features, such as voice mail, caller ID, and call waiting services. The Programming segment operates national programming networks consisting of E!, The Golf Channel, VERSUS, G4, and Style. The company also develops and operates Internet businesses focused on entertainment, information, and communication, including Comcast.net, Fancast, thePlatform, Fandango, Plaxo, and DailyCandy; and owns two professional sports teams and a multipurpose arena, as well as provides facilities management services, including food services, for sporting events, concerts, and other events. As of December 31, 2009, Comcast Corporation served approximately 23.6 million video customers, 15.9 million high-speed Internet customers, and 7.6 million phone customers, as well as approximately 50.6 million homes in 39 states and the District of Columbia. The company was founded in 1969 and is based in Philadelphia, Pennsylvania.

SAVIENT PHARMACEUTICALS INC (NASDAQ:SVNT) - Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the United States. The KRYSTEXXA is being developed as a treatment for chronic gout in patients refractory to conventional therapy. The company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It sells its products directly to drug wholesalers. The company, formerly known as Bio-Technology General Corp. and changed its name to Savient Pharmaceuticals, Inc. in June 2003. Savient Pharmaceuticals, Inc. was founded in 1980 and is headquartered in East Brunswick, New Jersey.

SKYWORKS SOLUTIONS INC (NASDAQ:SWKS) - Skyworks Solutions, Inc., together with its subsidiaries, offers analog and mixed signal semiconductors worldwide. The company provides power amplifiers and front-end solutions for cellular devices from entry level to multimedia platforms and smart phones. Its product portfolio consists of amplifiers, attenuators, detectors, diodes, directional couplers, front-end modules, hybrids, infrastructure RF subsystems, mixers/demodulators, phase shifters, PLLs/synthesizers/VCOs, power dividers/combiners, receivers, switches, and technical ceramics. Skyworks also offers MIS silicon chip capacitors, transceivers, and modulators. The company markets its products to automotive, broadband, cellular infrastructure, energy management, industrial, medical, military, and cellular handset applications. Skyworks sells its products primarily through its direct sales force, as well as through independent manufacturers representatives and distribution partners. The company was founded in 1962 and is headquartered in Woburn, Massachusetts.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641